TapImmune, Inc. (TPIV), an immunotherapy company, announced today that the company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application entitled, "A chimeric nucleic acid molecule with non-AUG initiation sequences."
The patent claims are for the Company's proprietary PolyStart™ technology which is a platform for the next-generation vaccine technology for the treatment of cancer or infectious diseases. It elevates the expression of any one or a multiplicity of T-cell antigenic epitopes by four fold or greater. This technology, possessing unlimited application in oncology and infectious diseases, not only in TapImmune's own platforms but can be applied to many others via licensing.
Specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease, the company’s Polystart technology is a unique vaccine platform antigen expression system that 'elevates' the expression and consequently the processing and presentation of the desired antigenic peptide for the stimulation of T-killer and/or T-helper cells to recognize and kill cancer cells.
"The allowed claims on this patent clearly position TapImmune to advance the clinical development of PolyStart, making it the third proprietary vaccine technology in our pipeline,” said Dr. Glynn Wilson, Chairman & CEO of TapImmune. “We are very excited about this technology, as we believe it marks a next generation of T-cell vaccines."
In recent months, the company has reported a number of positive developments, including:
- Presenting at the Biotech Showcase 2016 in San Francisco.
- Relocating its corporate headquarters from Seattle, Washington, to Jacksonville, Florida.
Furthermore, earlier this month, the FDA granted TapImmune its valued Fast Track label for TPIV 200, which provides special treatment to move the drug more quickly through the regulatory process with expedited review when considering TPIV 200's application for approval.
"We believe that the FDA's decision to grant Fast Track designation to TPIV 200 for the treatment ovarian cancer significantly expedites our clinical development program. We look forward to starting Phase II trials in the near future to address this highly aggressive cancer", said Wilson.
According to the American Cancer Society, 21,290 women were diagnosed with ovarian cancer last year. TapImmune’s continued progress with its lead Polystart technology is positioned to bring hope to those fighting this devastating disease. "We believe that TPIV 200 has the potential to improve outcomes for ovarian cancer patients, said Wilson, “for whom current treatment modalities offer a relative short time to recurrence and a poor overall prognosis".
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer